Department of Plastic and Reconstructive Surgery, Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy.
Aesthetic Plast Surg. 2012 Feb;36(1):180-5. doi: 10.1007/s00266-011-9771-3. Epub 2011 Jun 30.
Facial lipoatrophy is a stigmatizing hallmark of HIV. The injection of facial fillers has an essential role in the treatment of this condition. The objective of our study was to verify the safety and efficacy of a new formulation of high-density hyaluronic acid for the injectable treatment of HIV-related facial lipoatrophy.
We treated with high-density hyaluronic acid injections HIV patients affected by moderate to severe facial lipoatrophy and evaluated them at last follow-up, at a minimum of 36 weeks. Physician-related outcomes included pre-and post-treatment ultrasound measurement of the soft-tissue thickness of the cheeks and qualitative assessment of aesthetic results by means of the Global Aesthetic Improvement Scale using pre- and post-treatment photos of the patients. Patient satisfaction outcomes were evaluated with the VAS-face scale and Freiburg test.
Fifty-four patients were studied. The median number of treatment sessions was 3 and the median length of treatment was 5.5 months. The thickness of the soft tissues of the cheek increased significantly from 9.45 to 13.12 mm (p<0.0001). On the basis of the Global Aesthetic Improvement Scale, 87.5% of the patients were judged as "much improved" or "improved." Patient satisfaction at 1 year from the end of treatment was proven (VAS-face: 77.9; Freiburg questionnaire: 93.6% of patients were satisfied or very satisfied). Complications were limited to mild redness and swelling in the early postoperative period.
Long-term improvement of facial contour and excellent patient satisfaction, in the absence of severe side effects, were obtained by the injection of high-density hyaluronic acid (STYLAGE® XL) in HIV patients with facial lipoatrophy.
面部脂肪萎缩是 HIV 的一个标志性特征。面部填充物的注射在治疗这种疾病方面起着重要作用。我们的研究目的是验证新型高密度透明质酸在治疗 HIV 相关面部脂肪萎缩方面的安全性和有效性。
我们用高密度透明质酸注射治疗受中重度面部脂肪萎缩影响的 HIV 患者，并在至少 36 周的最后一次随访时对他们进行评估。医生相关的结果包括脸颊软组织厚度的治疗前后超声测量和使用患者治疗前后的照片通过全球美学改善量表对美学结果进行定性评估。通过 VAS 面部量表和弗莱堡测试评估患者的满意度结果。
研究了 54 名患者。治疗次数的中位数为 3 次，治疗的中位数长度为 5.5 个月。脸颊软组织的厚度从 9.45 增加到 13.12 毫米，显著增加（p<0.0001）。根据全球美学改善量表，87.5%的患者被评为“明显改善”或“改善”。治疗结束后 1 年的患者满意度得到证实（VAS 面部量表：77.9；弗莱堡问卷：93.6%的患者满意或非常满意）。并发症仅限于术后早期的轻度红肿。
通过向 HIV 面部脂肪萎缩患者注射高密度透明质酸（STYLAGE®XL），获得了面部轮廓的长期改善和极好的患者满意度，而没有严重的副作用。
